Hims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?

Key Takeaways HIMS expects 2025 EPS growth of 170.4% vs. LFMD's 107.6%, signaling stronger profit momentum. HIMS is expanding into Europe via its ZAVA acquisition, targeting markets like Germany and France. LFMD's $299 Wegovy program has enrolled more than 75K patients, showing rapid traction and nationwide scale.Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space. This is bringing a new class of tech-driven innovators to the forefr ...